急性骨髄性白血病の世界市場レポート 2025年

急性骨髄性白血病市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.3％で50億2,000万米ドルに成長します。予測期間の成長は、標的療法、免疫療法開発、精密医療アプローチ、認知度の向上と早期発見、共同研究イニシアティブの進展によるものと考えられます。予測期間の主な動向には、最小残存病変モニタリングの重視、治療意思決定支援における人工知能（AI）の統合、支持療法とQOL介入の重視、共同研究イニシアティブと臨床試験、患者アドボカシーとエンパワーメントプログラムなどが含まれます。

アンメットニーズ市場の成長は、高齢者人口の増加とアンメットヘルスケアニーズの増加によってもたらされると予想されます。この成長は特に、急性骨髄性白血病のような健康問題に直面している65歳以上の高齢者人口に関連しています。2022年、米国がん協会（ACS）は、AMLが高齢者の間で流行しており、平均診断年齢が68歳で、生存率が著しく低いことを報告しました。AMLは2022年に約60,650人が罹患し、24,000人が死亡しました。したがって、高齢者人口と医療ニーズの高まりが急性骨髄性白血病市場の発展に寄与しています。

急性骨髄性白血病市場の成長は、個別化医療の採用増加によってさらに促進されます。この革新的な医療アプローチは、遺伝子、環境、ライフスタイルの個人差を考慮して治療やヘルスケアを行うものです。AMLの場合、個別化医療には分子プロファイリングが含まれ、各患者に固有の特定の遺伝子変異やバイオマーカーを特定します。この情報は、標的療法の選択とカスタマイズされた治療計画の指針となり、副作用を最小限に抑えながら介入効果を最適化します。2022年、米国食品医薬品局（FDA）の医薬品評価研究センター（CDER）は37の新規分子生物学的製剤（NME）を承認し、その約34％は個別化医療連合（PMC）によって個別化医薬品に分類されました。したがって、個別化医療の採用が増加していることが、急性骨髄性白血病市場の成長を促進する要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界急性骨髄性白血病 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の急性骨髄性白血病市場：成長率分析
• 世界の急性骨髄性白血病市場の実績：規模と成長, 2019-2024
• 世界の急性骨髄性白血病市場の予測：規模と成長, 2024-2029, 2034F
• 世界急性骨髄性白血病総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の急性骨髄性白血病市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法
• 放射線治療
• 幹細胞移植
• 標的療法
• 世界の急性骨髄性白血病市場化学療法によって、実績と予測, 2019-2024, 2024-2029F, 2034F
• シタラビン
• アントラサイクリン系薬剤
• アルキル化剤
• 代謝阻害物質
• チロシンキナーゼ阻害剤
• ホルモン療法
• 世界の急性骨髄性白血病市場レジメン別、実績と予測, 2019-2024, 2024-2029F, 2034F
• DCレジメン
• AVDレジメン
• VCDレジメン
• 世界の急性骨髄性白血病市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 小売店ドラッグストア
• 外来診療センター
• クリニック
• 世界の急性骨髄性白血病市場化学療法の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 導入化学療法
• 強化化学療法
• 世界の急性骨髄性白血病市場、放射線治療の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 全身照射
• 局所放射線療法
• 世界の急性骨髄性白血病市場幹細胞移植の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 自家幹細胞移植
• 同種幹細胞移植
• 世界の急性骨髄性白血病市場、標的療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• チロシンキナーゼ阻害剤（TKI）
• モノクローナル抗体
• その他の標的エージェント

第7章 地域別・国別分析

• 世界の急性骨髄性白血病市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の急性骨髄性白血病市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 急性骨髄性白血病市場：競合情勢
• 急性骨髄性白血病市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi-Aventis（Genzyme Corporation）Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol Myers Squibb Company
• GlaxoSmithKline plc
• Takeda Pharmaceuticals
• Amgen Inc.
• Otsuka Holdings Co. Ltd.
• Teva Pharmaceutical
• Celgene Corporation
• Astellas Pharma
• Servier Pharmaceuticals
• CSPC Pharmaceutical Group
• Genmab AS
• Zhejiang Medicine Co. Ltd.
• Syndax Pharmaceuticals Inc.
• Astex Pharmaceuticals Inc.
• MEI Pharma Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 急性骨髄性白血病市場2029：新たな機会を提供する国
• 急性骨髄性白血病市場2029：新たな機会を提供するセグメント
• 急性骨髄性白血病市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Acute myeloid leukemia (AML) is a form of blood cancer arising from abnormal white blood cell development in the bone marrow. AML is characterized by the presence of myeloblasts, also known as leukemic blasts, leading to an excessive production of immature white blood cells. This abnormal cell proliferation fills the bone marrow, hindering the production of healthy blood cells.

The primary treatment modalities for acute myeloid leukemia encompass chemotherapy, radiation therapy, stem cell transplant, and targeted therapy. Chemotherapy involves the use of potent drugs to eliminate rapidly dividing cells in the body. Various chemotherapeutic agents employed in the treatment of AML include cytarabine, anthracycline drugs, alkylating agents, anti-metabolites, tyrosine kinase inhibitors, and hormonal therapy. These drugs are administered in different regimens such as DC regimen, AVD regimen, and VCD regimen. Acute myeloid leukemia treatment is provided by various end-users, including hospitals, retail drug stores, ambulatory care centers, and clinics.

The acute myeloid leukemia market research report is one of a series of new reports from The Business Research Company that provides acute myeloid leukemia market statistics, including acute myeloid leukemia industry global market size, regional shares, competitors with an acute myeloid leukemia market share, detailed acute myeloid leukemia market segments, market trends and opportunities, and any further data you may need to thrive in the acute myeloid leukemia industry. This acute myeloid leukemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acute myeloid leukemia market size has grown strongly in recent years. It will grow from $3.5 billion in 2024 to $3.79 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to growth aging population, environmental factors, genetic predisposition, limited treatment options, medical advancements.

The acute myeloid leukemia market size is expected to see strong growth in the next few years. It will grow to $5.02 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to growing advancements in targeted therapies, immunotherapies development, precision medicine approaches, increased awareness and early detection, collaborative research initiatives. Major trends in the forecast period include emphasis on minimal residual disease monitoring, integration of artificial intelligence (ai) in treatment decision support, focus on supportive care and quality of life interventions, collaborative research initiatives and clinical trials, patient advocacy and empowerment programs.

The anticipated growth in the acute myeloid leukemia market is driven by the expanding older population base and increasing unmet healthcare needs. This growth is particularly associated with the elderly population, aged 65 and above, facing health issues such as acute myeloid leukemia. In 2022, the American Cancer Society USA (ACS) reported that AML was prevalent among the elderly, with an average diagnosis age of 68 and notably low survival rates. AML affected around 60,650 individuals in 2022, resulting in 24,000 deaths. Hence, the geriatric population base and the rising healthcare needs contribute to the advancement of the acute myeloid leukemia market.

The growth of the acute myeloid leukemia market is further propelled by the increasing adoption of personalized medicine. This innovative medical approach takes into account individual variations in genes, environments, and lifestyles for treatment and healthcare. In the case of AML, personalized medicine involves molecular profiling to identify specific genetic mutations and biomarkers unique to each patient. This information guides the selection of targeted therapies and customized treatment plans, optimizing intervention effectiveness while minimizing adverse effects. In 2022, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), with approximately 34% classified as personalized medicines by the Personalized Medicine Coalition (PMC). Hence, the rising adoption of personalized medicine is a key driver for the growth of the acute myeloid leukemia market.

A notable trend in the acute myeloid leukemia market is the increasing focus on research and development (R&D) by pharmaceutical groups. R&D efforts aim to develop improved products and services to meet the demands of drug development. For example, a clinical trial titled 'Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs. Physician's Choice in Newly Diagnosed FLT3-ITD+ AML (Q-SOC)' is in Phase III, initiated in November 2021, and expected to conclude by March 2025, according to the National Library of Medicine.

Major companies in the acute myeloid leukemia market are concentrating on the development of advanced drug solutions, such as maintenance monotherapy, to enhance their product portfolios and address unmet medical needs. Maintenance monotherapy involves administering a single therapeutic agent as an ongoing, long-term therapy to prevent the recurrence or progression of a medical condition. In July 2023, Daiichi Sankyo Company Limited received approval from the United States Food and Drug Administration (USFDA) for quizartinib (Vanflyta) as maintenance monotherapy for newly diagnosed AML in adults with FLT3 internal tandem duplication (ITD)-positive status. The approval is based on positive results from the QuANTUM-First trial, demonstrating a significant improvement in overall survival. The dosage of quizartinib varies during induction, consolidation, and maintenance phases, and it is not indicated as maintenance monotherapy following allogeneic hematopoietic stem cell transplantation.

In March 2023, QIAGEN partnered with Servier Laboratories for an undisclosed amount to develop a companion diagnostic test for TIBSOVO, an isocitrate dehydrogenase-1 (IDH1) inhibitor intended for AML treatment. This collaboration aims to create and validate a real-time in vitro PCR test designed to detect IDH1 gene mutations in AML patients, using blood and bone marrow samples. The partnership enhances global accessibility to TIBSOVO for AML patients with IDH1 mutations and underscores QIAGEN's role in developing companion diagnostics for emerging biomarkers in onco-hematology, supporting precision medicine initiatives. Servier Laboratories, a France-based pharmaceutical company, is a key player in this collaboration.

Major companies operating in the acute myeloid leukemia market include Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Novartis AG, Sanofi-Aventis (Genzyme Corporation), Bristol Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceuticals, Amgen Inc., Otsuka Holdings Co. Ltd., Teva Pharmaceutical, Celgene Corporation, Astellas Pharma, Servier Pharmaceuticals, CSPC Pharmaceutical Group, Genmab AS, Zhejiang Medicine Co. Ltd., Syndax Pharmaceuticals Inc., Astex Pharmaceuticals Inc., MEI Pharma Inc., SELLAS Life Sciences Group, Ambit Biosciences Corporation, Agios Pharmaceuticals Inc., Neomed Management AS, Oncolyze Inc., TC BioPharm, VERASTEM INC., Mirati Therapeutics Inc., Sunshine Lake Pharma, Sunesis Pharmaceuticals Inc.

North America was the largest region in the acute myeloid leukemia market in 2024. The regions covered in the acute myeloid leukemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the acute myeloid leukemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The acute myeloid leukemia market includes revenue earned by drugs such as DC regimen, AVD Regimen, VCD regimen, cytarabine, vidaza, dacogen, midostaurin, quizartinib, vosaroxin that are used for the treatment of acute myeloid leukemia. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acute Myeloid Leukemia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acute myeloid leukemia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acute myeloid leukemia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acute myeloid leukemia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Chemotherapy; Radiation therapy; Stem Cell Transplant; Targeted Therapy
• 2) By Chemotherapy: Cytarabine; Anthracycline Drugs; Alkylating Agents; Anti-metabolites; Tyrosine Kinase Inhibitors; Hormonal Therapy
• 3) By Regimen: DC Regimen; AVD Regimen; VCD Regimen
• 4) By End-User: Hospital; Retails Drug Stores; Ambulatory Care Centers; Clinics
• Subsegments:
• 1) By Chemotherapy: Induction Chemotherapy; Consolidation Chemotherapy
• 2) By Radiation Therapy: Total Body Irradiation; Localized Radiation Therapy
• 3) By Stem Cell Transplant: Autologous Stem Cell Transplant; Allogeneic Stem Cell Transplant
• 4) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs); Monoclonal Antibodies; Other Targeted Agents
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; AbbVie Inc.; Novartis AG; Sanofi-Aventis (Genzyme Corporation)
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Acute Myeloid Leukemia Market Characteristics

3. Acute Myeloid Leukemia Market Trends And Strategies

4. Acute Myeloid Leukemia Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Acute Myeloid Leukemia Growth Analysis And Strategic Analysis Framework

• 5.1. Global Acute Myeloid Leukemia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Acute Myeloid Leukemia Market Growth Rate Analysis
• 5.4. Global Acute Myeloid Leukemia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Acute Myeloid Leukemia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Acute Myeloid Leukemia Total Addressable Market (TAM)

6. Acute Myeloid Leukemia Market Segmentation

• 6.1. Global Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Radiation therapy
• Stem Cell Transplant
• Targeted Therapy
• 6.2. Global Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cytarabine
• Anthracycline Drugs
• Alkylating Agents
• Anti-metabolites
• Tyrosine Kinase Inhibitors
• Hormonal Therapy
• 6.3. Global Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• DC Regimen
• AVD Regimen
• VCD Regimen
• 6.4. Global Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Retails Drug Stores
• Ambulatory Care Centers
• Clinics
• 6.5. Global Acute Myeloid Leukemia Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Induction Chemotherapy
• Consolidation Chemotherapy
• 6.6. Global Acute Myeloid Leukemia Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Total Body Irradiation
• Localized Radiation Therapy
• 6.7. Global Acute Myeloid Leukemia Market, Sub-Segmentation Of Stem Cell Transplant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Autologous Stem Cell Transplant
• Allogeneic Stem Cell Transplant
• 6.8. Global Acute Myeloid Leukemia Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tyrosine Kinase Inhibitors (TKIs)
• Monoclonal Antibodies
• Other Targeted Agents

7. Acute Myeloid Leukemia Market Regional And Country Analysis

• 7.1. Global Acute Myeloid Leukemia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Acute Myeloid Leukemia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Acute Myeloid Leukemia Market

• 8.1. Asia-Pacific Acute Myeloid Leukemia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Acute Myeloid Leukemia Market

• 9.1. China Acute Myeloid Leukemia Market Overview
• 9.2. China Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Acute Myeloid Leukemia Market

• 10.1. India Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Acute Myeloid Leukemia Market

• 11.1. Japan Acute Myeloid Leukemia Market Overview
• 11.2. Japan Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Acute Myeloid Leukemia Market

• 12.1. Australia Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Acute Myeloid Leukemia Market

• 13.1. Indonesia Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Acute Myeloid Leukemia Market

• 14.1. South Korea Acute Myeloid Leukemia Market Overview
• 14.2. South Korea Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Acute Myeloid Leukemia Market

• 15.1. Western Europe Acute Myeloid Leukemia Market Overview
• 15.2. Western Europe Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Acute Myeloid Leukemia Market

• 16.1. UK Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Acute Myeloid Leukemia Market

• 17.1. Germany Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Acute Myeloid Leukemia Market

• 18.1. France Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Acute Myeloid Leukemia Market

• 19.1. Italy Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Acute Myeloid Leukemia Market

• 20.1. Spain Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Acute Myeloid Leukemia Market

• 21.1. Eastern Europe Acute Myeloid Leukemia Market Overview
• 21.2. Eastern Europe Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Acute Myeloid Leukemia Market

• 22.1. Russia Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Acute Myeloid Leukemia Market

• 23.1. North America Acute Myeloid Leukemia Market Overview
• 23.2. North America Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Acute Myeloid Leukemia Market

• 24.1. USA Acute Myeloid Leukemia Market Overview
• 24.2. USA Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Acute Myeloid Leukemia Market

• 25.1. Canada Acute Myeloid Leukemia Market Overview
• 25.2. Canada Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Acute Myeloid Leukemia Market

• 26.1. South America Acute Myeloid Leukemia Market Overview
• 26.2. South America Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Acute Myeloid Leukemia Market

• 27.1. Brazil Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Acute Myeloid Leukemia Market

• 28.1. Middle East Acute Myeloid Leukemia Market Overview
• 28.2. Middle East Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Acute Myeloid Leukemia Market

• 29.1. Africa Acute Myeloid Leukemia Market Overview
• 29.2. Africa Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Acute Myeloid Leukemia Market Competitive Landscape And Company Profiles

• 30.1. Acute Myeloid Leukemia Market Competitive Landscape
• 30.2. Acute Myeloid Leukemia Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi-Aventis (Genzyme Corporation) Overview, Products and Services, Strategy and Financial Analysis

31. Acute Myeloid Leukemia Market Other Major And Innovative Companies

• 31.1. Bristol Myers Squibb Company
• 31.2. GlaxoSmithKline plc
• 31.3. Takeda Pharmaceuticals
• 31.4. Amgen Inc.
• 31.5. Otsuka Holdings Co. Ltd.
• 31.6. Teva Pharmaceutical
• 31.7. Celgene Corporation
• 31.8. Astellas Pharma
• 31.9. Servier Pharmaceuticals
• 31.10. CSPC Pharmaceutical Group
• 31.11. Genmab AS
• 31.12. Zhejiang Medicine Co. Ltd.
• 31.13. Syndax Pharmaceuticals Inc.
• 31.14. Astex Pharmaceuticals Inc.
• 31.15. MEI Pharma Inc.

32. Global Acute Myeloid Leukemia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Acute Myeloid Leukemia Market

34. Recent Developments In The Acute Myeloid Leukemia Market

35. Acute Myeloid Leukemia Market High Potential Countries, Segments and Strategies

• 35.1 Acute Myeloid Leukemia Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Acute Myeloid Leukemia Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Acute Myeloid Leukemia Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer